2.
几项胸腺癌化疗的试验结果
Results of several trials about chemotherapy efficacy in thymic carcinoma
| Author | Regimen | Number of patients (n) | Response rate (%) | MST(year) |
| ADOC: cisplatin+adriamycin+vincristine+cyclophosphamide; CODE: cisplatin+vincristine+adrinmycin+etoposide; PC: paclitaxel+carboplatin; MST: median survival time; NR: no report. | ||||
| Koizumi[29] | ADOC (cisplatin 50 mg/m2, d1; adriamycin 40 mg/m2, d1; vincristine 0.6 mg/m2, d3; cyclophosphamide 700 mg/m2, d4; q3-4 weeks) | 8 | 75 | 1.6 |
| Yoh[30] | CODE (cisplatin 25 mg/m2, weekly; vincristine 1 mg/m2, weeks 1, 2, 4, 6, 8; doxorubicin 40 mg/m2, weeks 1, 3, 5, 7, 9; etoposide 80 mg/m2, for 3 days during weeks 1, 3, 5, 7, 9) | 12 | 42 | 3.8 |
| Maruyama[31] | PC (paclitaxel 200 mg/m2, carboplatin AUC6, q3 weeks) | 6 | 100 | NR |
| Lemma[27] | PC (paclitaxel 225 mg/m2, carboplatin AUC5, q3 weeks) | 21 | 24 | 1.25 |
| Lgawa[32] | PC (paclitaxel 200 mg/m2, carboplatin AUC6, q3 weeks) | 11 | 36 | 1.8 |